Inhibikase Therapeutics (IKT) Net Equity Issued and Repurchased (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $110.5 million (up 7.21% YoY), while the FY2025 annual figure was $107.6 million, up 4.0% from the prior year.
• Net Equity Issued and Repurchased eased to $2.9 million in Q1 2026 per IKT's latest filing, from $107.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $107.6 million in Q4 2025 and bottomed at $70.0 in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $20.2 million across 4 years, with a median of $1.0 million in 2023.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased jumped 22053983.85% — and 2025, when it sank 100.0%.
• Inhibikase Therapeutics' Net Equity Issued and Repurchased stood at $452.0 in 2023, then surged by 22053983.85% to $99.7 million in 2024, then climbed by 7.96% to $107.6 million in 2025, then sank by 97.31% to $2.9 million in 2026.
• Business Quant data shows IKT's Net Equity Issued and Repurchased at $2.9 million in Q1 2026, $107.6 million in Q4 2025, and $150.0 in Q2 2025.